Actively Recruiting
Study of Dulaglutide to Prevent Heart Injury After Non-Cardiac Surgery A Phase 4 Trial for Adults Undergoing Elective Surgery
Led by The University of Hong Kong · Updated on 2026-05-04
372
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Myocardial injury after non-cardiac surgery MINS is a serious cause of complications and death, detected by high-sensitive troponin tests after surgery and linked to increased risk of death within 30 days. Researchers are evaluating whether pre-operative treatment with glucagon-like peptide-1 receptor agonists GLP-1 RAs, specifically Dulaglutide, can reduce MINS in patients undergoing elective intermediate to high risk non-cardiac surgery. This trial is an open-label, multi-center, randomized controlled study involving 372 patients to assess the potential benefits of this intervention. Participants will be randomly assigned in a 21 ratio to either receive a single subcutaneous dose of Dulaglutide 0.75mg between 1 and 14 days before surgery plus routine peri-operative care, or to receive routine peri-operative care alone. The study drug, Dulaglutide, is being evaluated for its effects on heart injury and blood sugar stability during surgery. All patients will receive standard care throughout the study period. During the study, participants will undergo physical, respiratory, and cardiac assessments including electrocardiograms and blood tests for cardiac enzymes. Researchers will monitor myocardial injury within 72 hours after surgery as the primary outcome, and assess cardiovascular events, safety, and related measures within 30 days. The trial will also evaluate troponin levels, heart attacks, strokes, and mortality, with close follow-up during hospitalization and up to 30 days after randomization.
CONDITIONS
Brief Title
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Research Team
C
Chun Ka Wong, Clinical Assistant Professor
L
Lily Hung, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here